We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Apremilast

News List

QLHC Concludes Apremilast Not Likely to Reduce Time to COVID Recovery, Mortality americanpharmaceuticalreview
March 22, 2021
Quantum Leap Healthcare Collaborative (QLHC), the sponsor of the I-SPY COVID Trial, announced that apremilast (Otezla), made by Amgen, has been dropped for futility.
Unichem Laboratories gets USFDA approval for Apremilast Tablets expresspharma
February 20, 2021
Unichem Laboratories has received ANDA approval for its Apremilast Tablets, 10 mg, 20 mg and 30 mg from the United States Food and Drug Administration (USFDA) to market a generic version of Amgen’s Otezla (apremilast) Tablets, 10 mg, 20 mg, and 30 mg.
FDA Approves Otezla (apremilast) for the Treatment of Oral Ulcers Associated with Behçet’s Disease drugs
July 22, 2019
FDA Approves Otezla (apremilast) for the Treatment of Oral Ulcers Associated with Behçet’s Disease.